Form 4: Mirum Pharma COO's Routine Stock Transactions
Insider Transaction Report
Mirum Pharmaceuticals' President and COO, Peter Radovich, reported the vesting of performance restricted stock units and subsequent sale of shares to cover tax obligations.
Summary
- Peter Radovich, President and COO of Mirum Pharmaceuticals, Inc. (MIRM), reported transactions involving the company's common stock.
- On March 15, 2026, Radovich acquired 7,220 shares of common stock upon the vesting of performance restricted stock units (PRSUs).
- Also on March 15, 2026, Radovich acquired an additional 23,000 shares of common stock from the vesting of other PRSUs.
- On March 16, 2026, Radovich disposed of 16,515 shares of common stock at a price of $91.9779 per share.
- This disposition was specifically to cover tax withholding obligations associated with the vesting of the performance restricted stock units.
- Following these reported transactions, Radovich directly beneficially owns 40,272 shares of common stock.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, typical for executive compensation and tax management, with no direct positive or negative implications for the company's operational performance or strategic direction.
Positives
- The vesting of performance restricted stock units (PRSUs) indicates the achievement of performance criteria, aligning executive incentives with company goals.
Negatives
- A portion of vested shares was sold to cover tax withholding obligations, reducing the reporting person's direct beneficial ownership.
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions, providing transparency into executive stock ownership changes. These transactions, particularly those for tax withholding, are common and generally do not reflect a change in management's long-term view of the company, but rather a routine part of equity compensation.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Authorization | Peter Radovich granted a Power of Attorney to specific individuals at Mirum Pharmaceuticals, Inc. (Doug Sheehy, Jody Howe, and Judit Ryvkin) to prepare, execute, and submit SEC Forms 3, 4, 5, and 144 on his behalf. | 03/10/2026 | Streamlines compliance with Section 16(a) of the Exchange Act and Rule 144 of the Securities Act for the reporting person, ensuring timely and accurate filings. |
Legal Proceedings
- NA
Related Party Transactions
- The vesting of performance restricted stock units and subsequent sale of shares to cover tax obligations are transactions between an officer (Peter Radovich) and the company (Mirum Pharmaceuticals, Inc.) as part of his compensation package.
Stakeholder Impact
- Shareholders: Provides transparency regarding executive stock ownership changes.
- Employees: Demonstrates the company's equity compensation structure for executives.
Next Steps
- Future vesting of remaining performance restricted stock units on March 15, 2027.
Key Dates
| Date | Description |
|---|---|
| 03/15/2025 | Vesting date for 2/3 of the shares from one set of performance restricted stock units. |
| 03/10/2026 | Date Peter Radovich executed the Power of Attorney. |
| 03/15/2026 | Acquisition of 7,220 and 23,000 shares of common stock upon vesting of performance restricted stock units; also a vesting date for 1/3 of shares from one set of PRSUs and 2/3 of shares from another set of PRSUs. |
| 03/16/2026 | Sale of 16,515 shares of common stock to cover tax withholding obligations. |
| 03/17/2026 | Date the Form 4 was signed by the Attorney-in-Fact. |
| 03/15/2027 | Future vesting date for 1/3 of the shares from one set of performance restricted stock units. |
Recommendation
holdThis Form 4 filing details routine insider transactions related to executive compensation and tax obligations. It does not provide new information regarding the company's financial performance, strategic direction, or operational health that would warrant a change in investment recommendation. The transactions are expected and do not signal a shift in the executive's confidence or a material change in the company's outlook.
Keywords
Mirum Pharmaceuticals, MIRM, Peter Radovich, Form 4, insider trading, stock transactions, restricted stock units, executive compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.